A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85

Jens Overgaard; Hanne Sand Hansen; Marie Overgaard; Lars Bastholt; Anne Berthelsen; Lena Specht; Birgit Lindeløv; Karsten Juhl Jørgensen

doi:10.1016/s0167-8140(97)00220-x

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85

Authors: Jens Overgaard, Hanne Sand Hansen, Marie Overgaard, Lars Bastholt, Anne Berthelsen, Lena Specht, Birgit Lindeløv, Karsten Juhl Jørgensen - Radiotherapy and Oncology 1998 cited by 567

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 | Litlas